{"success":true,"data":{"pressRelease":{"id":"52925","rtpr_id":"nGNX8MTW0Q","ticker":"STIM","exchange":"NASDAQ","all_tickers":["STIM"],"title":"Neuronetics Appoints Robert Greene as Senior Vice President Sales","author":"Globe Newswire","published_at":"2026-06-02T20:30:00.199Z","article_body":"MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:\nSTIM), a medical technology company focused on designing, developing, and\nmarketing products that improve the quality of life for patients who suffer\nfrom neurohealth disorders and the maker of NeuroStar® Advanced Therapy,\ntoday announced that Robert Greene has been appointed as the company’s\nSenior Vice President Sales, effective June 1, 2026.\n\nRob brings extensive experience leading commercial strategy and sales\norganizations within healthcare and medical technology, including capital\nequipment and service.\n\nInducement Grant under Nasdaq Listing Rule 5635(c)(4)\n\nIn connection with his hiring on June 1, 2026, the Compensation Committee of\nthe Company’s Board of Directors authorized the grant to Mr. Greene of\nrestricted stock units representing 200,000 shares of the Company’s common\nstock in accordance with Nasdaq Listing Rule 5635(c)(4), which will vest in\nfour equal annual installments on the anniversary of the grant date, subject\nto Mr. Greene’s continued employment with the company and subject to\nCapitalization Adjustments (as defined in the Company’s 2020 Inducement\nIncentive Plan).\n\nAbout Neuronetics\n\nNeuronetics, Inc. believes that mental health is as important as physical\nhealth. As a global leader in neuroscience, Neuronetics is delivering more\ntreatment options to patients and physicians by offering exceptional in-office\ntreatments that produce extraordinary results. NeuroStar Advanced Therapy is a\nnon-drug, noninvasive treatment that can improve the quality of life for\npeople suffering from neurohealth conditions when traditional medication has\nnot helped. In addition to selling the NeuroStar Advanced Therapy System and\nassociated treatment sessions to customers, Neuronetics operates Greenbrook\nTMS Inc. (“Greenbrook”) treatment centers across the United States,\noffering NeuroStar Advanced Therapy for the treatment of major depressive\ndisorder (“MDD”) and other mental health disorders. NeuroStar Advanced\nTherapy is the leading transcranial magnetic stimulation (“TMS”) treatment\nfor MDD in adults, and is backed by the largest clinical data set of any TMS\ntreatment system for depression, including the world’s largest depression\noutcomes registry. Greenbrook treatment centers also offer SPRAVATO®\n(esketamine) nasal spray, a prescription medicine indicated for the treatment\nof treatment-resistant depression in adults as monotherapy or in conjunction\nwith an oral antidepressant. It is also indicated for depressive symptoms in\nadults with major depressive disorder with acute suicidal ideation or behavior\nin conjunction with an oral antidepressant.(1)\n\nThe NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug\nAdministration for adults with MDD, as an adjunct for adults with\nobsessive-compulsive disorder, to decrease anxiety symptoms in adult patients\nwith MDD that may exhibit comorbid anxiety symptoms (anxious depression), and\nas a first line adjunct for the treatment of MDD in adolescent patients aged\n15-21. For safety information and indications for use, visit NeuroStar.com\n(https://www.globenewswire.com/Tracker?data=y8W4lUnjq04M3NZWrypRleIOAKWivEYlaZ52c9qoWtwo8tkj8nm7805vchqBQmNJsVQSvPRBxJChD7gTucwBWA==).\n\nInvestors:\n\nMike Vallie or Mark Klausner \nICR Healthcare\n443-213-0499\nir@neuronetics.com\n\nMedia:\nEvolveMKD\n646-517-4220\nNeuroStar@evolvemkd.com\n\nReferences\n(1 )The effectiveness of SPRAVATO® in preventing suicide or in reducing\nsuicidal ideation or behavior has not been demonstrated. Use of\nSPRAVATO® does not preclude the need for hospitalization if clinically\nwarranted, even if patients experience improvement after an initial dose of\nSPRAVATO®. For more important safety information about SPRAVATO®, please\nvisit spravatohcp.com\n(https://www.globenewswire.com/Tracker?data=SuDR525hdhq8yV8Xc772PQI6RaPUbEATNZo57LG1_-dVyUS9IQP4Io83F-poPTs-PThlpodwRGb8R0_AMNQNAIQPW4kozrQCv5XA7xV364GE8BexIcktBcDd_r8EqtsvBIkBL96-cIeL_QbU8aGy1rUYbZhsCyKiRLP0Hen3PtyAhA6ydCetIWuMi2zr_m1zj6nV9mDKDTPEUekAfXAA_tH7VCFC0yDqXY4J9qVydDZucpcmWT2oTrl6ke-mf64b7RTKMbC3XxtGvbCRygUIRDKi9hK9ijHv3p0lmU49mx3ax_tqBNppxXCq7OCLgNJz8KeJbFaEKcYjWqRJuDIO0dykW2jsZb_9iMvr1IiUeKgMJTkzUbZ5koLmA7pmex-0dByWzfPnFKYF7jSDsYAzfjkq8Fi2mXp0M_jc_CptdSOp4gVb1Ytr2dg_aqscDQTKYOh9--AfpVeeDqjjNh6s6VS75sI3DvdNk-zf0peuT1-SGJ68-jo8z0VnEPiCnJGJYSUj4VOWKzuzgcEzwGeZU5t9oTEZqu19XXD0aXASEa8jBEs_IcIB_pkRxL343_suf-S9TaxCtl4OwzjK8o8T970Cca5yBIHP5XLZDc5UDBiauWzCwGoZZHvEY1x1ZbSi-suXMNX1Qss7OfPYpj9y2nLhZNCyx6D0ydaGGg-Vq7sOOxcbTX43XvLt4LbxJRKrGtYqgvMMTkaVtd_ICURAf4mvjqllIviBuVCWdXHd5J2wdqwDm9Vd6AMb40gQ1C0AQXlO8fTV8wTmuqwyxqOLFg==).\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/12db9039-d4bf-41a0-8b4a-324398e392b4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8MTW0Q","title":"Neuronetics Appoints Robert Greene as Senior Vice President Sales","author":"Globe Newswire","ticker":"STIM","created":"2026-06-02T20:30:00.199Z","tickers":["STIM"],"exchange":"NASDAQ","article_body":"MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:\nSTIM), a medical technology company focused on designing, developing, and\nmarketing products that improve the quality of life for patients who suffer\nfrom neurohealth disorders and the maker of NeuroStar® Advanced Therapy,\ntoday announced that Robert Greene has been appointed as the company’s\nSenior Vice President Sales, effective June 1, 2026.\n\nRob brings extensive experience leading commercial strategy and sales\norganizations within healthcare and medical technology, including capital\nequipment and service.\n\nInducement Grant under Nasdaq Listing Rule 5635(c)(4)\n\nIn connection with his hiring on June 1, 2026, the Compensation Committee of\nthe Company’s Board of Directors authorized the grant to Mr. Greene of\nrestricted stock units representing 200,000 shares of the Company’s common\nstock in accordance with Nasdaq Listing Rule 5635(c)(4), which will vest in\nfour equal annual installments on the anniversary of the grant date, subject\nto Mr. Greene’s continued employment with the company and subject to\nCapitalization Adjustments (as defined in the Company’s 2020 Inducement\nIncentive Plan).\n\nAbout Neuronetics\n\nNeuronetics, Inc. believes that mental health is as important as physical\nhealth. As a global leader in neuroscience, Neuronetics is delivering more\ntreatment options to patients and physicians by offering exceptional in-office\ntreatments that produce extraordinary results. NeuroStar Advanced Therapy is a\nnon-drug, noninvasive treatment that can improve the quality of life for\npeople suffering from neurohealth conditions when traditional medication has\nnot helped. In addition to selling the NeuroStar Advanced Therapy System and\nassociated treatment sessions to customers, Neuronetics operates Greenbrook\nTMS Inc. (“Greenbrook”) treatment centers across the United States,\noffering NeuroStar Advanced Therapy for the treatment of major depressive\ndisorder (“MDD”) and other mental health disorders. NeuroStar Advanced\nTherapy is the leading transcranial magnetic stimulation (“TMS”) treatment\nfor MDD in adults, and is backed by the largest clinical data set of any TMS\ntreatment system for depression, including the world’s largest depression\noutcomes registry. Greenbrook treatment centers also offer SPRAVATO®\n(esketamine) nasal spray, a prescription medicine indicated for the treatment\nof treatment-resistant depression in adults as monotherapy or in conjunction\nwith an oral antidepressant. It is also indicated for depressive symptoms in\nadults with major depressive disorder with acute suicidal ideation or behavior\nin conjunction with an oral antidepressant.(1)\n\nThe NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug\nAdministration for adults with MDD, as an adjunct for adults with\nobsessive-compulsive disorder, to decrease anxiety symptoms in adult patients\nwith MDD that may exhibit comorbid anxiety symptoms (anxious depression), and\nas a first line adjunct for the treatment of MDD in adolescent patients aged\n15-21. For safety information and indications for use, visit NeuroStar.com\n(https://www.globenewswire.com/Tracker?data=y8W4lUnjq04M3NZWrypRleIOAKWivEYlaZ52c9qoWtwo8tkj8nm7805vchqBQmNJsVQSvPRBxJChD7gTucwBWA==).\n\nInvestors:\n\nMike Vallie or Mark Klausner \nICR Healthcare\n443-213-0499\nir@neuronetics.com\n\nMedia:\nEvolveMKD\n646-517-4220\nNeuroStar@evolvemkd.com\n\nReferences\n(1 )The effectiveness of SPRAVATO® in preventing suicide or in reducing\nsuicidal ideation or behavior has not been demonstrated. Use of\nSPRAVATO® does not preclude the need for hospitalization if clinically\nwarranted, even if patients experience improvement after an initial dose of\nSPRAVATO®. For more important safety information about SPRAVATO®, please\nvisit spravatohcp.com\n(https://www.globenewswire.com/Tracker?data=SuDR525hdhq8yV8Xc772PQI6RaPUbEATNZo57LG1_-dVyUS9IQP4Io83F-poPTs-PThlpodwRGb8R0_AMNQNAIQPW4kozrQCv5XA7xV364GE8BexIcktBcDd_r8EqtsvBIkBL96-cIeL_QbU8aGy1rUYbZhsCyKiRLP0Hen3PtyAhA6ydCetIWuMi2zr_m1zj6nV9mDKDTPEUekAfXAA_tH7VCFC0yDqXY4J9qVydDZucpcmWT2oTrl6ke-mf64b7RTKMbC3XxtGvbCRygUIRDKi9hK9ijHv3p0lmU49mx3ax_tqBNppxXCq7OCLgNJz8KeJbFaEKcYjWqRJuDIO0dykW2jsZb_9iMvr1IiUeKgMJTkzUbZ5koLmA7pmex-0dByWzfPnFKYF7jSDsYAzfjkq8Fi2mXp0M_jc_CptdSOp4gVb1Ytr2dg_aqscDQTKYOh9--AfpVeeDqjjNh6s6VS75sI3DvdNk-zf0peuT1-SGJ68-jo8z0VnEPiCnJGJYSUj4VOWKzuzgcEzwGeZU5t9oTEZqu19XXD0aXASEa8jBEs_IcIB_pkRxL343_suf-S9TaxCtl4OwzjK8o8T970Cca5yBIHP5XLZDc5UDBiauWzCwGoZZHvEY1x1ZbSi-suXMNX1Qss7OfPYpj9y2nLhZNCyx6D0ydaGGg-Vq7sOOxcbTX43XvLt4LbxJRKrGtYqgvMMTkaVtd_ICURAf4mvjqllIviBuVCWdXHd5J2wdqwDm9Vd6AMb40gQ1C0AQXlO8fTV8wTmuqwyxqOLFg==).\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/12db9039-d4bf-41a0-8b4a-324398e392b4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-02T20:30:00.240059556Z","server_sent_at_ms":1780432200240},"received_at":"2026-06-02T20:30:00.481Z","source_url":null},"analysis":{"id":"42354","press_release_id":"52925","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Neuronetics appointed Robert Greene as Senior Vice President of Sales, effective June 1, 2026.\n\nGreene brings extensive experience leading commercial strategy and sales organizations in healthcare and medical technology.\n\nThe Compensation Committee authorized an inducement grant of 200,000 restricted stock units, vesting in four equal annual installments.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine commercial hire for STIM; watch for sales execution updates in upcoming earnings."},"keyFigures":{"customDimensions":{"vesting_period_years":4,"inducement_grant_shares":200000}},"quotedText":"Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service.","namedEntities":{"people":[{"name":"Robert Greene","role":"Senior Vice President Sales"}],"products":["NeuroStar Advanced Therapy","SPRAVATO"],"companies":[{"name":"Neuronetics, Inc.","ticker":"STIM"},{"name":"Greenbrook TMS Inc.","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Appointment of a Senior VP of Sales is a routine commercial leadership hire. The 200,000-share inducement grant is standard for this level but represents minor dilution; no strategic pivot or crisis signal is present."},"tickerRelevance":{"others":[],"primary":"STIM"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_executive_hire","sectorWeight":"moderate","dilutionImpact":"minor"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Neuronetics appointed Robert Greene as Senior Vice President of Sales, effective June 1, 2026.\n\nGreene brings extensive experience leading commercial strategy and sales organizations in healthcare and medical technology.\n\nThe Compensation Committee authorized an inducement grant of 200,000 restricted stock units, vesting in four equal annual installments.","key_figures":{"customDimensions":{"vesting_period_years":4,"inducement_grant_shares":200000}},"named_entities":{"people":[{"name":"Robert Greene","role":"Senior Vice President Sales"}],"products":["NeuroStar Advanced Therapy","SPRAVATO"],"companies":[{"name":"Neuronetics, Inc.","ticker":"STIM"},{"name":"Greenbrook TMS Inc.","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T20:31:32.239Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_executive_hire","sectorWeight":"moderate","dilutionImpact":"minor"}},"durationMs":43507,"modelName":"george-droid-qwen-72b"}}